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Note on nomenclature. 
In spite of the IUPAC recommendations, polyphenol compounds will be described in this paper as the 
2,3,4- or 3,4,5- isomers referred to the position 1- of the linking moieties (acid, amine or alcohol) acting 
as directing group in the numbering.  
 
General methods.  
All reactions were carried out with magnetic stirring in round-bottomed flasks unless otherwise noted. Air 
or moisture-sensitive reactions were conducted in oven-dried glassware under a positive pressure of dry 
argon. All solvents were pre-dried, freshly distilled prior to use as specifically described
1
 and stored over 
Linde-type activated 4Å molecular sieves. All organic extracts were dried over anhydrous MgSO4 or 
Na2SO4, filtered and concentrated in a rotary evaporator under vacuo. Brine refers to saturated aqueous 
NaCl solution. Analytical thin layer chromatography (TLC) was performed on pre-coated aluminum silica 
gel plates 60 (F254, 0.25 mm, Merck). Spots of products were visualized from the TLC under UV lamps at 
254 or 360 nm or by heating on a hot plate (aprox. 200 ºC) after treatment with the suitable developer 
solutions. The following general developers were used in order to visualize compounds from the TLC 
plates: CAM (refers to an aqueous solution of cerium ammonium molybdate (Hanessian’s stain)), PMA 
and vanillin (refer to a 5% methanolic solution of phosphomolybdic acid and vanillin, respectively). 
Nitrogen-containing compounds were selectively visualized by dipping with ninhydrine solution while 
carbonyl-containing compounds were selectively visualized with dinitro-phenylhydrazine (DNP). Oils or 
waxy solids were converted into foams by repeated freeze-drying (lyophilization) from acetonitrile or 
DMSO and traces of water for better handling of the products.  
Debenzylation of the benzyl-protected phenols was performed in a Parr-hydrogenator working at 25 ºC 
and 3.1 bar (45 psi). High-pressure hydrogenation of nitriles in 9 to yield tetra-amine 22 was performed 
on a H-Cube® Continuous-flow Hydrogenation Reactor using Co-Raney as catalyst immobilized in a 
CatCart®-Catalyst Cartridge System (both from Thales Nano). Microwave-mediated reactions were 
performed using an Initiator
TM
 2.0 single-mode cavity reactor from Biotage (Uppsala, Sweden). 
Microwave experiments were carried out in sealed microwave process vials utilizing the standard 
absorbance level (400 W maximum power). The temperature was measured with an IR sensor on the 
outside of the reaction vessel.  
Commercially available reagents were purchased and used as received from the suppliers without further 
purification unless otherwise stated in the text. Pentaerythritol (A), 2,3,4- and 3,4,5-trihydroxybenzoic 
acids, acrylonitrile, tert-butyl acrylate, 2,2-dimethyl-1,3-propanediol (B) and 1,1,1-
tris(hydroxymethyl)ethane (C) were purchased from Sigma-Aldrich.  
Known compounds were synthesized according to the described procedures, slightly modified if required. 
Their properties and spectroscopic data were fully consistent with the reported data in the literature. 
Benzyl 3,4,5-tribenzyloxybenzoate and 3,4,5-tribenzyloxybenzoic acid were synthesized as described
2
; 
2,3,4-tribenzyloxyphenol (36) was obtained as previously reported.
3
 Tetradentate scaffolds were 
synthesized following known procedures: tetrakis-(5-carboxy-2-oxabutyl) methane (10)
4
, tetrakis-(5-
hydroxy-2-oxapentyl) methane (24)
5
 and tetraacetylenic scaffold 42
6
. Tridentate scaffolds 11
7
 and 25
8
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were synthesized according to known procedures. Bidentate scaffolds 12
9
 and 26
10
 were obtained as 
previously described. 
Separations were performed when required by preparative medium pressure flash column 
chromatography
11
 on silica gel 60 (PF254, 230-400 mesh, Merck) or by preparative Centrifugal Circular 
Thin-Layer Chromatography (CCTLC) on a Chromatotron™ (Kiesegel 60 PF254 gipshaltig, layer 
thickness of 1 mm, flow rate 2.5 mL min
-1
). Large scale chromatographic purifications were conducted on 
an automated flash purification system apparatus (Biotage Isolera One) using Varian cartridges 
(SuperFlash SF25-60 g, Si50). 
HPLC analyses were carried out using either a Waters Alliance HPLC/MS system (separation module 
model 2695, PDA (Photo Diode Array) detector model 2996 and micromass ZQ detector) (quoted as 
HPLC/MS) using a Xbridge C18 column (2.1 mm x 100 mm, 3.5 μm; eluting with acetonitrile (0.08% 
formic acid)/water (0.1% formic acid) mixtures as the mobile phases, flow rate, 250 µL/min) or on an 
Agilent 1120 compact apparatus equipped with a 1260 infinity PDA detector (quoted as HPLC) using an 
ACE 5 C18-300 column (4.6 x 15 mm, 3.5 μm) eluting with acetonitrile/water (both acidified with 0.05% 
TFA) at a flow rate of 1 mL/min. All retention times are quoted in minutes.  
Isolated compounds were dried under vacuo overnight with P2O5. Elemental analyses were performed by 
the Analysis Central Service, Centro de Química Orgánica “Lora Tamayo” with a Carlo Erba CHN-1108 
microanalyzer. A variation of a ±0.4% is admitted. Mass spectra (low and high-resolution) were 
registered in a quadrupole mass spectrometer Hewlett-Packard model 1100 equipped with an electrospray 
source. Positive or negative modes were used as required by the nature of the compound. Melting points 
were measured on a Mettler Toledo model MP70 melting point apparatus at a temperature increase rate of 
1 ºC/min and are uncorrected. Lyophilised (freeze dry) compounds melt at a wide range of temperatures. 
Debenzylated compounds (free-phenols) generally indicated decomposition (brown-black coloured 
sample) prior to melt. 
 
NMR procedures.  
Monodimensional NMR spectra were obtained using standard conditions on Varian INOVA-300, -400, 
UNITY-500, MERCURY-400 or Bruker AVANCE-300 NMR spectrometers using CDCl3 or methanol-d4 
as solvents. Solvents used in NMR experiments contains higher deuteration degree than 99.5% and were 
filtered through a pad of basic alumina (aluminium oxide 90, 70-230 mesh, Merck) in order to eliminate 
traces of water and acids prior to use. 
1
H-NMR chemical shifts for protons are reported in parts per 
million (ppm) downfield from tetramethylsilane referred to protonated residual peaks or specific signals 
due to deuterated solvents as internal references ( = 7.26 or 3.35 ppm for 1H NMR spectra in CDCl3 or 
CD3OD, respectively, and  = 77.0 or 49.3 ppm for 
13
C NMR in the same solvents). J values were 
expressed in Hz. 
1
H and 
13
C NMR chemical shifts for proton-decoupled carbons are reported in parts per 
million (ppm) referenced to the deuterated solvents as internal standards. The following abbreviations are 
used to describe peaks: s (singlet), d (doublet), t (triplet), qt (quartet), qn (quintet), sext (sextuplet), m 
(multiplet) and br (broad).  
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Proton and carbon assignments were based on DEPT, HSQC, HMQC, HMBC, gradient-COSY and NOE-
differential experiments. Homonuclear 2D spectra were acquired in the phase-sensitive mode. Data were 
collected in a 1024 x 256 matrix with a spectral width of 5000 Hz and a 2s recycle delay and processed in 
a 1024 x 1024 matrix. 2D Inverse proton detected heteronuclear shift correlation spectra, gHSQC and 
gHMBC, were obtained with the following conditions: data were collected in a 4096 x 128 matrix with a 
spectral width of 8000 Hz in the proton domain and 25000 Hz in the carbon domain, and processed in a 
4096 x 512 matrix. The gHSQC experiment was optimized for one bond heteronuclear coupling constant 
of 145 Hz. The gHMBC experiment was optimized for long range coupling constants of 8 Hz. Copies of 
NMR spectra (
1
H and 
13
C) were edited using MestReNova software (version 8.0.2-11021).  
 
Experimental procedures and characterization. 
 
Benzyl 2,3,4-tris(benzyloxy)benzoate (2) 
 
To a solution of 2,3,4-trihydroxybenzoic acid (1) (5 g, 29.4 mmol) in acetone (300 mL; 10 mL/mmol) at 
room temperature was added K2CO3 (20.3 g, 147 mmol), benzyl bromide (17.5 mL, 147 mmol) and NaI 
(4.4 g, 29.4 mmol). The mixture was refluxed for 16 hours, cooled to room temperature and quenched 
with H2O (50 mL). The crude was concentrated under reduced pressure in order to eliminate acetone, 
diluted further with additional amounts of H2O (50 mL) and extracted with EtOAc (3 x 10 mL/mmol). 
Organics layers were dried over anhydrous Na2SO4, filtered and concentrated to give a crude material that 
was purified by recrystallization from EtOH affording 2 (12.5 g, 23.5 mmol, 81%) as a white solid. mp. 
59.1-61.3 ºC; TLC (Rf = 0.44 hexane/EtOAc (2:1) v/v; CAM); 
1
H NMR (300 MHz, CDCl3) δ: 7.58 (d, J 
= 8.9 Hz, 1 H), 7.35-7.18 (m, 20 H), 6.71 (d, J = 8.9 Hz, 1 H), 5.2 (s, 2 H), 5.06 (s, 2 H), 5.01 (s, 2 H), 
4.94 (s, 2 H); 
13
C NMR (75 MHz, CDCl3) δ: 165.4, 156.6, 153.9, 142.6, 137.2, 136.1, 128.8, 127.3, 
118.7, 108.7, 76.3, 75.6, 70.8, 66.6; m/z (ESI
+
): 1083 [100%, (2M+Na)
+
], 553 [47%, (M+Na)
+
], 531 
[81%, (M+H)
+
]; Anal. calcd for C35H30O5 (530.6): C, 79.22; H, 5.70; found: C, 78.98; H, 5.90; 
HPLC/MS: tR = 5.1 min., polar gradient CH3CN/H2O from (70:30) up to (100:0) in 5 min (97% purity). 
 
2,3,4-tris(benzyloxy)benzoic acid (3)
12
 
 
Perbenzylated compound 2 (7.2 g, 13.6 mmol) was dissolved in a solution of 3 N KOH in MeOH (360 
mL, 26 mL/mmol) and refluxed overnight. The mixture was cooled to room temperature and acidified to 
pH = 3-4 by careful addition of 3 N HCl aqueous solution. The resulting precipitate was filtered, 
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redissolved in EtOAc (100 mL) and washed with H2O (50 mL). The aqueous phase was extracted with 
CH2Cl2 (3 × 10 mL/mmol) and the combined organic layers were dried over Na2SO4, filtered and 
concentrated. The acid 3 was isolated as a white solid after recrystallization from MeOH (5.80 g, 13.2 
mmol, 97%). mp: 148-150 ºC; TLC (Rf = 0.6 EtOAc/MeOH (9:1) v/v; PMA); 1H NMR (300 MHz, 
CDCl3) δ: 7.91 (d, J = 8.9 Hz, 1 H), 7.5-7.3 (m, 15 H), 6.93 (d, J = 9.0 Hz, 1 H), 5.31 (s, 2 H,), 5.21 (s, 2 
H), 5.11 (s, 2 H); 
13
C NMR (75 MHz, CDCl3) δ: 165.5, 157.4, 152.0, 140.8, 136.6, 135.7, 134.7, 129.3, 
127.5, 115.4, 109.5, 77.7, 75.8, 71.0 ppm; m/z (ESI
+
) 463 [100%, (M+Na)
+
], 441 [21%, (M+H)
+
]; Anal. 
calcd for C28H24O5 (440.5): C, 76.35; H, 5.49; found: C, 76.43; H, 5.51; HPLC/MS: tR = 4.47 min., polar 
gradient CH3CN/H2O from (70:30) up to (100:0) in 5 min (96% purity). Spectroscopic properties of this 
compound were consistent with the data reported in the literature
12
. 
 
 
Preparation of Carbamates. Curtius Rearrangement. General Procedure. 
To a solution of suitable benzoic acid (1 equiv) in toluene (5 mL/mmol) under argon was added DPPA 
(1.1 equiv) and Et3N (1.1 equiv) at room temperature. The mixture was heated at 75 ºC until complete 
disappearance of the starting material (as monitored by TLC), yielding the isocyanate intermediate 4 (not 
isolated). Then, the corresponding alcohols or amines were added (1.2 equiv per isocyanate group to be 
functionalised). The reaction was stirred additionally at 75 ºC overnight (monitored by TLC), cooled to 
room temperature and subsequently washed with a 1 N aqueous solution of HCl and then with a saturated 
aqueous solution of NaHCO3, dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude was purified as determined.  
 
Benzyl (2,3,4-tris(benzyloxy)phenyl) carbamate (5) 
 
Following the general procedure, a solution of acid 3 (4.1 g, 9.4 mmol), DPPA (2.2 mL, 10.3 mmol) and 
Et3N (1.4 mL, 10.3 mmol) in toluene (47 mL) provided isocyanate 4, which was treated with benzyl 
alcohol (1.2 mL, 11.3 mmol). The crude mixture was purified by recrystallization in MeOH to yield 5 
(3.93 g, 8.65 mmol, 92%) as a white solid. mp. 76.9-78.1 ºC; TLC (Rf = 0.65 hexane/EtOAc (2:1) v/v; 
CAM); 
1
H NMR (400 MHz, CDCl3) δ: 7.8 (br d, 1 H), 7.5-7.3 (m, 20 H), 7.0 (br s, 1 H), 6.8 (d, J = 9.2 
Hz, 1 H), 5.2 (s, 2 H), 5.13 (s, 2 H), 5.12 (s, 2 H), 5.11 (s, 2 H); 
13
C NMR (100 MHz, CDCl3) δ: 153.2, 
148.4, 141.7, 141.6, 137.3, 136.9, 136.7, 136.2, 128.6, 128.5, 128.4, 128.3, 128.1, 128.0, 127.9, 127.5, 
126.1, 113.4, 109.7, 75.9, 75.5, 71.3, 66.6; m/z (ESI
+
) 568 (100%, [M + Na]
+
), 546 (36%, [M + H]
+
); 
Anal. calcd for C35H31NO5 (545.6): C, 77.04; H, 5.73; N, 2.57; found: C, 77.38; H, 6.01; N, 2.70; 
HPLC/MS: tR = 4.9 min., polar gradient CH3CN/H2O from (70:30) up to (100:0) in 5 min (99% purity).  
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Methyl (2,3,4-tris(benzyloxy)phenyl)carbamate (6a) 
 
 
According to the general procedure, acid 3 (1.55 g, 3.5 mmol), DPPA (830 µL, 4 mmol) and Et3N (540 
µL, 4 mmol) in toluene (18 mL) were reacted to form isocyanate intermediate 4, which was treated with 
methanol (170 L, 0.4 mmol). After work-up, the crude mixture was purified by CCTLC (polar gradient 
on elution using EtOAc/hexane from (5:95) up to (20:80)) and further recrystallized from MeOH to yield 
6a (1.22 g, 2.6 mmol, 74%) as a white solid. mp. 89.1-90.7; TLC (Rf = 0.34 hexane/EtOAc (4:1) v/v; 
CAM); 
1
H NMR (400 MHz, CDCl3) δ: 7.7 (br d, 1 H), 7.4-7.3 (m, 15 H), 6.89 (br s, 1 H), 6.76 (d, J = 9.2 
Hz, 1 H), 5.09 (s, 4 H), 5.08 (s, 2 H), 3.71 (s, 3 H); 
13
C NMR (100 MHz, CDCl3) δ: 154.0, 148.4, 141.7, 
137.3, 137.0, 136.8, 128.6, 128.5, 128.4, 128.3, 128.1, 127.9, 127.5, 126.2, 113.4, 109.8, 75.8, 75.6, 71.4, 
52.2; m/z (ESI
+
) 492 (59%, [M + Na]
+
), 470 (100%, [M + H]
+
); Anal. calcd for C29H27NO5 (469.5): C, 
74.18; H, 5.80; N, 2.98; found: C, 74.27; H, 6.02; N, 3.20.  
 
Preparation of 2,3,4-tris(benzyloxy) aniline (7) from carbamate precursors.  
 
 
 
Method A. Reaction with TBAF. Specific method for benzyl-carbamate deprotection. 
Cbz-protected aniline 5 (1.1 g, 2 mmol) was dissolved in dry, freshly distilled THF (5 mL) under argon 
atmosphere at room temperature. A solution of TBAF in THF (1 M solution, 30 mL, 15 equiv) was added 
and the reaction mixture was heated at 60º C overnight. TLC monitoring indicated complete deprotection 
of carbamate. Volatiles were removed under vacuo and the residue embedded in a pad of celite and 
directly purified by column chromatography on SiO
2
 (hexane/EtOAc (2:1) v/v as eluent).
13
 Free amine 7 
was isolated as a waxy solid, converted into a white foam after repeated freeze-dry from CH3CN/H2O 
(627 mg, 1.5 mmol, 76%). TLC (Rf = 0.32; hexane/EtOAc (3:2) v/v; CAM); 
1
H NMR (400 MHz, CDCl3) 
δ: 7.45-7.3 (m, 15 H), 6.6 (d, J = 8.8 Hz, 1H), 6.49 (d, J = 8.8 Hz, 1H), 5.1 (s, 2H), 5.07 (s, 2H), 5.04 (s, 
2H); 
13
C NMR (100 MHz, CDCl3) δ: 145.5, 143.4, 140.8, 137.9, 137.8, 137.7, 135.5, 128.6, 128.5, 128.4, 
128.2, 128.0, 127.9, 127.8, 111.7, 110.1, 75.7, 75.2, 72.5; m/z (ESI
+
) 434 (26%, [M + Na]
+
), 412 (100%, 
[M + H]
+
); HPLC/MS: tR = 2.55 min. polar gradient CH3CN/H2O from (70:30) up to (100:0) in 5 min 
(98% purity). 
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Method B. Alkaline hydrolysis of carbamates. General Procedure 
A 40% solution of KOH in methanol (5 mL/mmol) was added to the methyl carbamate 6a (1 g, 1.83 
mmol). The slurry was stirred under reflux overnight (monitored by TLC). Then, it was cooled to room 
temperature and the solvent was halved, diluted with H2O (10 mL/mmol) and extracted with EtOAc (3 × 
10 mL/mmol). Combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated 
under vacuum to yield the desired free amine 7, which was triturated from cold diethyl ether, dried and 
isolated as a yellowish solid, which was used without further purification (736 mg, 1.79 mmol, 98%). 
Isolated compound 7 by this method B is identical to the obtained by the method A.  
 
This general procedure (method B) was used also for the deprotection of ethyl (3,4,5-
tris(benzyloxy)phenyl) carbamate yielding 3,4,5-tribenzyloxy aniline 16 (90%) which fitted the 
spectroscopic data reported in the literature for this compound.
14,15
 
 
Preparation of aniline hydrochlorides 8 and 16. General procedure. 
The free amine was redissolved in Et2O and a 1 N solution of HCl in Et2O was added dropwise until an 
abundant precipitate is formed. The precipitate was filtered off, gently washed with additional amounts of 
Et2O and then efficiently dried to give a solid that did not need further purification. Hydrochlorides 8 and 
16 can be stored without noticeable degradation for months if kept in a cool and dry place. 
 
2,3,4-tris(benzyloxy)aniline hydrochloride (8) 
 
Following the general procedure, aniline 7 was converted into its hydrochloride 8, isolated as a pale 
brownish solid. mp. 174.9-176.2 ºC; 
1
H NMR (400 MHz, CDCl3) δ: 10.0 (br s, 3 H), 7.5 (d, J = 4.2 Hz, 2 
H), 7.4-7.2 (m, 11 H), 7.2 (br d, J = 9.4 Hz, 1 H), 7.1 (dd, J = 5.1, 1.6 Hz, 2 H), 6.6 (d, J = 9.0 Hz, 1 H), 
5.3 (s, 2 H), 5.1 (s, 2 H), 5.0 (s, 2 H); 
13
C NMR (100 MHz, CDCl3) δ: 152.8, 146.0, 142.2, 136.8, 136.6, 
136.3, 128.7, 128.6, 128.3, 128.2, 127.9, 127.5, 118.9, 118.3, 109.3, 75.9, 75.6, 71.2; m/z (ESI
+
): 823 
(30%, [2M – HCl + H]+), 413 (38%, [M – HCl + 2H]+, 412 (100%, [M – HCl + H]+). 
 
3,4,5-Tris(benzyloxy)aniline hydrochloride (16) 
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The general procedure was also used for the synthesis of 3,4,5-tris(benzyloxy) aniline hydrochloride (16) 
(96% yield). mp. 173.6-175.2 ºC; 
1
H NMR (400 MHz, CD3OD) δ: 7.45 (d, J = 7.1 Hz, 4 H), 7.41-7.34 
(m, 8 H), 7.25 (d, J = 7.1 Hz, 3 H), 6.73 (s, 2 H), 5.16 (s, 4 H), 5.02 (s, 2 H);
 13
C NMR (100 MHz, 
CD3OD) δ: 155.5, 139.1, 138.3, 130.4, 130.2, 129.8, 129.7, 129.2, 104.0, 76.7, 72.8; m/z (ESI
+
) 824 
(18%, [2M – HCl + 2H]+), 414 (100%, [M – HCl + 3H]+). 
 
Amide-linked derivatives 
 
Scheme 1. Synthesis of amide-linked compounds 13-15 and 16-21. 
 
*3,4,5-trihydroxy aniline isomer used; ** N-Me derivative; *** Synthesized from Ac2O in Py;  
**** Synthesized from the acyl chlorides (EtCOCl and C16H31COCl) in Py/dichloromethane. 
 
Acetylation. N-(2,3,4-tris(benzyloxy)phenyl)acetamide (19a) 
 
To a solution of free aniline 7 (60 mg, 0.15 mmol, 1 equiv) in pyridine (0.3 mL; 3 mL/mmol) was added 
acetic anhydride (41 µL, 0.44 mmol, 3 equiv). The reaction mixture was stirred at room temperature until 
complete disappearance of the starting material (overnight) as indicated by TLC monitoring. The mixture 
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was carefully acidified with 1 N HCl aqueous solution reaching a pH = 2. Then, the aqueous phase was 
extracted with CH2Cl2 (4 × 10 mL), dried over Na2SO4, filtered and concentrated under vacuum to give a 
crude that was purified by CCTLC (polar gradient EtOAc/hexane from (5:95) up to (50:50) v/v) affording 
19a (65 mg, 0.14 mmol, 98%) as a yellowish oil. TLC (Rf = 0.32 hexane/EtOAc (3:2) v/v; CAM); 
1
H 
NMR (400 MHz, CDCl3) δ: 8.0 (d, J = 9.4 Hz, 1 H), 7.5-7.3 (m, 16 H), 6.8 (d, J = 9.0 Hz, 1 H), 5.12 (s, 2 
H), 5.11 (s, 2 H), 5.10 (s, 2 H), 1.9 (s, 3 H);
 13
C NMR (75 MHz, CDCl3) δ: 167.9, 149.2, 142.4, 141.8, 
137.7, 137.4, 137.2, 129.0, 128.9, 128.7, 128.6, 128.3, 128.2, 127.8, 126.7, 115.2, 110.1, 76.6, 75.8, 71.7, 
24.6; m/z (ESI
+
): 476 (37%, [M + Na]
+
), 454 (100%, [M + H]
+
).
 
 
Preparation of monodentate amides 20a-21a from acyl chlorides. General Procedure.  
To a solution of amine hydrochloride 8 (1 equiv) in dry CH2Cl2 (10 mL/mmol) was added pyridine (2 
equiv) and the corresponding acyl chloride (0.95 equiv) at 0 ºC (ice-bath). The reaction mixture was 
stirred and let warm from 0 ºC to room temperature until complete disappearance of the starting material. 
The crude material was successively washed with H2O (10 mL/mmol), aqueous saturated solution of 
NaHCO3 (10 mL/mmol) and brine (10 mL/mmol), dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude was purified as specifically determined. 
 
N-(2,3,4-tris(benzyloxy)phenyl)propionamide (20a) 
 
A solution of the amine hydrochloride 8 (43 mg, 0.1 mmol), pyridine (16 µL, 0.2 mmol) and propionyl 
chloride (8.0 µL, 0.09 mmol) in CH2Cl2 (1.0 mL) was treated as described in the general procedure. The 
crude was purified by CCTLC (EtOAc/hexane 5%-50%) to afford 20a (37 mg, 0.08 mmol, 81%) as a 
white solid after freeze dry. mp. 67.8-71.5 ºC; TLC (Rf = 0.35 hexane/EtOAc (3:2) v/v; CAM); 
1
H NMR 
(400 MHz, CDCl3) δ: 7.98 (d, J = 9.4 Hz, 1 H), 7.46-7.30 (m, 16 H), 6.75 (d, J = 9.4 Hz, 1 H), 5.10 (s, 4 
H), 5.09 (s, 2 H), 2.13 (qt, J = 7.6 Hz, 2 H), 1.08 (t, J = 7.6 Hz, 3 H); 
13
C NMR (100 MHz, CDCl3) δ: 
171.5, 148.8, 142.1, 141.4, 137.4, 137.0, 136.9, 128.8, 128.7, 128.6, 128.5, 128.4, 128.1, 127.9, 127.6, 
126.4, 114.8, 109.5, 76.4, 75.6, 71.3, 30.7, 9.6; m/z (ESI
+
) 490 (26%, [M + Na]
+
), 468 (100%, [M + H]
+
); 
Anal. calcd for C30H29NO4 (467.6): C, 77.06; H, 6.25; N, 3.00; found: C, 76.87; H, 6.55; N, 3.23. 
 
N-(2,3,4-tris(benzyloxy)phenyl)palmitamide (21a) 
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A solution of amine hydrochloride 8 (44 mg, 0.1 mmol), pyridine (16 µL, 0.2 mmol) and palmitoyl 
chloride (28 µL, 0.09 mmol) was treated as described in the general procedure. The crude reaction was 
purified by CCTLC (EtOAc/hexane 5%-20%) and recrystallized in CH3CN/H2O to yield 20a (43 mg, 
0.066 mmol, 68%) as a white solid. mp 90.2-91.1 ºC; TLC (Rf = 0.33 hexane/EtOAc (4:1) v/v; CAM); 
1
H 
NMR (400 MHz, CDCl3) δ: 7.98 (d, J = 9.1 Hz, 1 H), 7.52-7.27 (m, 16 H), 6.75 (d, J = 9.2 Hz, 1 H), 5.10 
(s, 2 H), 5.09 (s, 4 H), 2.09 (t, J = 7.6 Hz, 2 H), 1.56-1.52 (m, 2 H), 1.32-1.20 (m, 24 H), 0.88 (t, J = 6.8 
Hz, 3 H); 
13
C NMR (100 MHz, CDCl3) δ: 170.9, 148.8, 142.0, 141.4, 137.4, 137.1, 136.9, 128.8, 128.7, 
128.6, 128.5, 128.4, 128.1, 128.0, 127.5, 126.4, 114.8, 109.6, 76.3, 75.6, 71.3, 37.8, 31.9, 29.7, 29.6, 29.5, 
29.4, 29.3, 25.6, 22.7, 14.1; m/z (ESI
+
): 688 (43%, [M + K]
+
), 672 (34%, [M + Na]
+
), 650 (100%, [M + 
H]
+
); Anal. calcd for C43H55NO4 (649.9): C, 79.47; H, 8.53; N, 2.16; found: C, 79.71; H, 8.70; N, 2.28. 
 
PyBOP-mediated synthesis of multivalent amides 13a-15a and 17a. General Procedure.  
To a suspension of the suitable polyacid (1 mmol) in dry CH2Cl2 (20 mL/mmol) at 0 ºC (ice-bath) was 
added sequentially PyBOP (1.2 equiv per acid group) and Et3N (3.75 equiv per acid group) in a pressure 
tube. When the acid is solubilized (aprox. 5 min), aniline hydrochloride 8 (1.2 equiv per acid group) was 
added and the pressure tube sealed. The reaction mixture was warmed to 60 ºC and stirred overnight until 
consumption of the starting material (TLC monitoring). Then, reaction was cooled to room temperature, 
washed with a 10% citric acid aqueous solution and then with a 10% NaHCO3 aqueous solution, dried 
over anhydrous Na2SO4, filtered and concentrated under vacuo. The crude was purified as determined.  
 
Tetrakis [5-oxo-5-((2,3,4-tribenzyloxyphenyl)amino)-2-oxapentyl]methane (13a)  
 
A mixture of tetra-acid 10
4
 (21 mg, 0.050 mmol), hydrochloride 8 (108 mg, 0.240 mmol), PyBOP (126 
mg, 0.240 mmol) and Et3N (104 µL, 0.725 mmol) in CH2Cl2 (1 mL) was treated as described in the 
general procedure (reaction proceed at room temperature). The crude was purified by CCTLC 
(EtOAc/hexane 10-80%) to afford 13a (58 mg, 0.029 mmol, 58%) as a yellowish waxy foam after freeze-
drying. TLC (Rf = 0.26 hexane/EtOAc (2:3) v/v; CAM); 
1
H NMR (500 MHz, CDCl3) δ: 7.80 (br s, 4 H), 
7.75 (d, J = 9.3 Hz, 4 H), 7.41-7.27 (m, 60 H), 6.57 (d, J = 9.4 Hz, 4 H), 5.04 (s, 16 H), 5.01 (s, 8 H), 3.44 
(t, J = 5.7 Hz, 8 H), 3.18 (s, 8 H), 2.26 (t, J = 5.7 Hz, 8 H); 
13
C NMR (125 MHz, CDCl3) δ: 169.2, 149.2, 
142.6, 141.5, 137.4, 137.0, 136.8, 128.7, 128.6, 128.5, 128.3, 128.0, 127.9, 127.5, 126.1, 115.7, 109.4, 
76.1, 75.5, 71.2, 69.2, 67.0, 45.0, 37.7; m/z (ESI
+
) 1000 (100%, [1/2M + 2H]
+
); HRMS (ESI
+
) [M + H]
+
 
C125H121N4O20 requires 1997.8574, found: 1997.8568; Anal. calcd for C125H120N4O20 (1996.3): C, 75.13; 
H, 6.05; N, 2.80; found: C, 74.93; H, 6.13; N, 2.95. 
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1,1,1-tris [5-oxo-5-((2,3,4-tribenzyloxyphenyl)amino)-2-oxapentyl]ethane (14a) 
 
A solution of tri-acid 11 (17 mg, 0.05 mmol), hydrochloride 8 (108 mg, 0.24 mmol), PyBOP (126 mg, 
0.24 mmol) and Et3N (104 µl, 0.72 mmol) in CH2Cl2 (1.0 mL) was treated as described in the general 
procedure. The crude was purified by CCTLC (EtOAc/hexane 20-80%) to afford 16a (43 mg, 0.028 
mmol, 57%) as a yellowish wax. TLC (Rf = 0.21 hexane/EtOAc (2:3) v/v; CAM); 
1
H NMR (400 MHz, 
CDCl3) δ: 7.85 (d, J = 9.0 Hz, 3 H), 7.81 (br s, 3 H), 7.39-7.26 (m, 45 H), 6.65 (d, J = 9.3 Hz, 3 H), 5.02 
(s, 6 H), 5.01 (s, 6 H), 5.00 (s, 6 H), 3.44 (t, J = 5.8 Hz, 6 H), 3.06 (s, 6 H), 2.26 (t, J = 5.8 Hz, 6 H), 0.72 
(s, 3 H); 
13
C NMR (100 MHz, CDCl3) δ: 169.1, 149.0, 142.5, 141.4, 137.3, 137.0, 136.8, 128.7, 128.6, 
128.5, 128.3, 128.0, 127.9, 127.5, 126.2, 115.6, 109.4, 76.1, 75.5, 73.3, 71.1, 67.1, 40.5, 37.9, 17.3; m/z 
(ESI
+
) 1539 (11%, [M + Na]
+
), 845 (100%, [1/2M + 2MeOH + Na]
+
). 
 
2,2-bis [5-oxo-5-((2,3,4-tribenzyloxyphenyl)amino)-2-oxapentyl]propane (15a)  
 
A solution of di-acid 12 (25 mg, 0.1 mmol), hydrochloride 8 (106 mg, 0.24 mmol), PyBOP (126 mg, 0.24 
mmol) and Et3N (147 µl, 1.06 mmol) in CH2Cl2 (2 mL) was treated as described in the general procedure 
(heating was increased to 75 ºC). The crude mixture was purified by CCTLC (polar gradient 
EtOAc/CH2Cl2 from (0:100) up to (20:80)) to afford 15a (54 mg, 0.05 mmol, 52%) as a yellowish oil. 
TLC (Rf = 0.35 hexane/EtOAc (1:1) v/v; CAM); 
1
H NMR (400 MHz, CDCl3) δ: 7.93 (br s, 2 H), 7.89 (d, 
J = 9.1 Hz, 2 H), 7.43-7.29 (m, 30 H), 6.70 (d, J = 9.2 Hz, 2 H), 5.06 (s, 4 H), 5.05 (s, 8 H), 3.53 (t, J = 
5.9 Hz, 4 H), 3.04 (s, 4 H), 2.35 (t, J = 5.9 Hz, 4 H), 0.75 (s, 6 H); 
13
C NMR (100 MHz, CDCl3) δ: 169.3, 
149.0, 142.5, 141.4, 137.3, 137.0, 136.9, 128.7, 128.6, 128.5, 128.3, 128.0, 127.9, 127.5, 126.2, 115.6, 
109.4, 76.8, 76.0, 75.5, 71.2, 67.1, 38.1, 36.0, 22.0. m/z (ESI
+
) 1034 (7%, [M + H]
+
), 642 (100%, [M – 7 
+H2O + H]
+
). 
 
Tetrakis [5-oxo-5-((3,4,5-tribenzyloxyphenyl)amino)-2-oxapentyl]methane (17a) 
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A solution of tetra-acid 10 (21 mg, 0.050 mmol), hydrochloride 16 (108 mg, 0.24 mmol), PyBOP (126 
mg, 0.240 mmol) Et3N (104 µL, 0.72 mmol) in CH2Cl2 (1 mL) was treated as described in the general 
procedure. The crude was purified by CCTLC (EtOAc/hexane 40-100%) to afford 17a (73 mg, 0.037 
mmol, 73%) as a brownish solid. mp. 65.9-66.9 ºC; TLC (Rf = 0.30 hexane/EtOAc (1:3) v/v; CAM); 
1
H 
NMR (400 MHz, CDCl3) δ: 8.23 (s, 4 H), 7.37-7.20 (m, 60 H), 6.98 (s, 8 H), 4.96 (s, 16 H), 4.88 (s, 8H), 
3.52 (t, J = 5.4 Hz, 8 H), 3.21 (s, 8 H), 2.26 (t, J = 5.4 Hz, 8 H); 
13
C NMR (100 MHz, CDCl3) δ: 170.0, 
152.8, 137.7, 136.8, 134.8, 134.2, 128.5, 128.4, 128.1, 127.9, 127.8, 127.3, 99.9, 75.2, 71.0, 69.0, 66.8, 
45.2, 37.5; HRMS (ESI
-
) C125H119N4O20 requires M-H 1995.8418, found: 1995.8423; Anal. calcd for 
C125H120N4O20 (1996.3): C, 75.13; H, 6.05; N, 2.80; found: C, 74.92; H, 5.78; N, 2.65. 
 
Tetrakis [5-(methyl((3,4,5-tribenzyloxyphenyl)amino))-5-oxo-2-oxapentyl]methane (18a) 
 
A solution of 13a (60 mg, 0.03 mmol), MeI (75 µL, 1.2 mmol), KOH (67 mg, 1.2 mmol) and tetrabutyl 
ammonium bromide (TBABr, 20 mg, 0.06 mmol) in THF (0.8 mL; 25 mL/mmol) was stirred at room 
temperature overnight. Additional methyl iodide (40 equiv) was needed for the fully consumption of the 
starting material. The crude was diluted with THF, the inorganic precipitates were eliminated by filtration 
and the liquors were concentrated under vacuum. The residue was purified twice by CCTLC on 
immobilised silica gel (first purification: EtOAc/hexane 50-80%; second purification: EtOAC/CH2Cl2 20-
40%) to afford 18a (46 mg, 0.022 mmol, 73%) as a yellowish wax. TLC (Rf = 0.18 hexane/EtOAc (1:4) 
v/v; CAM); 
1
H NMR (300 MHz, CDCl3) δ: (some signals appear broadened and display fine splitting 
attributed to the presence of rotamers) 7.47-7.27 (m, 60 H), 6.87-6.82 (m, 4 H), 6.76 (d, J = 9.0 Hz, 4 H), 
5.10-5.02 (m, 24 H), 3.57 (dd, J = 14.8, 6.8 Hz, 4 H), 3.40 (dd, J = 13.5, 7.5 Hz, 4 H), 3.27 (s, 4 H), 3.21 
(s, 4 H), 3.08 (s, 6 H), 3.04 (s, 6 H), 2.30 (dt, J = 14.6, 7.1 Hz, 4 H), 2.02 (dt, J = 12.0, 5.7 Hz, 4 H); 
13
C 
NMR (75 MHz, CDCl3) δ: 171.6, 152.9, 148.9, 142.2, 137.0, 136.6, 131.0, 128.7, 128.5, 128.4, 128.2, 
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128.1, 127.6, 123.6, 109.0, 75.3, 71.0, 70.1, 68.0, 45.3, 33.9, 29.7; HRMS (ESI
-
) C129H127N4O20 requires 
M-H 2051.9044; found: 2051.9047. 
 
Tetrakis [5-(3-(2,3,4-tribenzyloxy)benzamido)-2-oxapentyl]methane (23a) 
 
A solution of tetra-amine 22 (68 mg, 0.19 mmol), acid 3 (394 mg, 0.9 mmol), PyBOP (466 mg, 0.9 
mmol) and Et3N (0.26 ml, 1.87 mmol) in dry CH2Cl2 (3.7 mL) was treated as described in the general 
procedure referred previously for the PyBOP-mediated synthesis of amides, but the reaction was heated at 
60 ºC. The crude was purified by CCTLC on immobilised silica gel (EtOAc/hexane 40-100%) to afford 
23a (206 mg, 0.100 mmol, 54%) as a white foam. TLC (Rf = 0.31 EtOAc 100%; CAM); 
1
H NMR (400 
MHz, CDCl3) δ: 7.85 (br d, J = 9.8 Hz, 4 H), 7.84 (d, J = 9.0 Hz, 4 H), 7.43-7.26 (m, 60 H), 6.83 (d, J = 
9.0 Hz, 4 H), 5.12 (s, 8 H), 5.10 (s, 8 H), 5.02 (s, 8 H), 3.32-3.23 (m, 16 H), 3.26 (s, 8 H), 1.53 (qn, J = 
6.1 Hz, 8 H); 
13
C NMR (100 MHz, CDCl3) δ: 165.1, 155.7, 151.8, 141.3, 137.4, 136.5, 129.0, 128.9, 
128.8, 128.6, 128.4, 127.8, 126.9, 120.3, 109.3, 77.2, 75.8, 71.0, 69.9, 69.3, 45.5, 37.4, 29.6; HRMS 
(ESI
+
) C129H129N4O20 requires MH 2053.9200, found: 2053.9191.  
 
Tetrakis (5-azido-2-oxapentyl)methane (27) 
 
To a solution of alcohol 24
5
 (670 mg, 1.8 mmol) in THF (36 mL, 20 mL/mmol) was added PPh3 (3.05 g, 
11.6 mmol), DIAD (2.3 mL, 11.6 mmol) and DPPA (2.5 mL, 11.6 mmol). The mixture was stirred at 60 
ºC overnight, cooled to room temperature and successively washed with a 1 N HCl aqueous solution and 
a saturated NaHCO3 aqueous solution. The organic phase was dried over Na2SO4, filtered and 
concentrated under vacuum to give a crude product that was purified by automated flash chromatography 
on silica gel (polar gradient on elution EtOAc/hexane from (5:95 up to 10:90)) to yield 27 (569 mg, 1.2 
mmol, 67%) as a colourless oil. TLC (Rf = 0.11 hexane/EtOAc (1:9) v/v; CAM); 
1
H NMR (300 MHz, 
CDCl3) δ: 3.5 (t, J = 5.9 Hz, 8 H), 3.37 (s, 8 H), 3.36 (t, J = 6.7 Hz, 8 H), 1.8 (qn, J = 6.3 Hz, 8 H). 
Spectroscopic properties of this compound were consistent with the data reported in the literature
5
. 
 
Tetrakis (5-amino-2-oxapentyl)methane (22) 
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Tetra-amine 22 can be obtained from tetra-azide 27 by standard hydrogenation (Pd/C, atmospheric 
pressure) as previously described.
5 
Alternatively, it can be synthesized from the parent tetranitrile 9 by 
reduction at high pressure in a continuous-flow apparatus. Thus, compound 9 (240 mg, 0.69 mmol) was 
dissolved in a 7 N solution of ammonia in MeOH (6 mL, 8.5 mL/mmol) and was flushed through a H-
Cube® continuous-flow hydrogenation reactor using a Raney-Cobalt catalyst immobilised in a cartridge 
at 70 ºC and 70 bars with a constant flow of hydrogen (1 mL/min). After two cycles, a sample of the 
crude was analysed by 
1
H-NMR, indicating complete reduction of the starting material. The reaction 
mixture was concentrated under reduced pressure to afford 22 (161 mg, 0.44 mmol, 63%) as a colourless 
oil. This compound was used in next step without further purification. 
1
H NMR (300 MHz, CD3OD) δ: 
3.47 (t, J = 6.0 Hz, 8 H), 3.38 (s, 8 H), 2.74 (t, J = 6.8 Hz, 8 H), 1.72 (qn, J = 6.3 Hz, 8 H). Spectroscopic 
properties of this compound were consistent with the data reported in the literature.
5
 
 
Carbamate- (28-31) and urea-linked (32-33) derivatives 
 
 
 
 
Scheme 2. Synthesis of carbamate- (28-31) and urea-linked (32-33) derivatives. 
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* yield not determinated as only a sample of the crude was purified for biological evaluation. 
 
Tetrakis [5-((2,3,4-tribenzyloxyphenyl)carbamoyl)oxy-2-oxapentyl]methane (28a) 
 
Following the general procedure, a solution of acid 3
12
 (478 mg, 1.1 mmol), DPPA (0.26 mL, 1.2 mmol) 
and Et3N (0.17 mL, 1.2 mmol) in toluene (5.4 mL) was reacted to form the isocyanate intermediate 4, 
which was treated with tetraol 24 (100 mg, 0.27 mmol) (stirred overnight at 75 ºC after addition of 24). 
Additional acid 3 (239 mg, 0.54 mmol), DPPA (0.13 mL, 0.6 mmol) and Et3N (83 mL, 0.6 mmol) were 
needed for the reaction to proceed to completion. After the usual work-up, the crude material was purified 
by CCTLC (polar gradient EtOAc/hexane from (10:90) up to (50:50)) to afford 28a (100 mg, 0.05 mmol, 
21%) as a yellowish oil. TLC (Rf = 0.4 hexane/EtOAc (2:3) v/v; CAM); 
1
H NMR (400 MHz, CDCl3) δ: 
7.66 (br s, 4 H), 7.42-7.29 (m, 60 H), 6.91 (br s, 4 H), 6.71 (d, J = 9.3 Hz, 4 H), 5.06 (s, 8 H), 5.05 (s, 8 
H), 5.04 (s, 8 H), 4.16 (t, J = 6.4 Hz, 8 H), 3.47 (t, J = 6.3 Hz, 8 H), 3.42 (s, 8 H), 1.87 (qn, J = 6.3 Hz, 8 
H); 
13
C NMR (100 MHz, CDCl3) δ: 153.5, 148.3, 141.8, 141.7, 137.4, 137.0, 136.9, 128.6, 128.5, 128.4, 
128.3, 128.0, 127.9, 127.5, 126.3, 113.6, 109.8, 75.9, 75.5, 71.4, 69.7, 67.6, 62.4, 45.3, 29.2; HRMS 
(ESI
+
) [M + Na]
+
 C129H128N4O24Na requires 2139.8816, found: 2139.8811.  
 
1,1,1-tris [5-((2,3,4-tribenzyloxyphenyl)carbamoyl)oxy-2-oxapentyl]ethane (29a) 
 
A solution of acid 3
12
 (296 mg, 0.7 mmol), DPPA (0.2 mL, 0.74 mmol) and Et3N (0.1 mL, 0.74 mmol) in 
toluene (3.4 mL) was reacted as described in the general procedure and treated with triol 25 (50 mg, 0.17 
mmol) (stirred overnight at 100 ºC after addition of triol). The crude was purified by CCTLC (polar 
gradient EtOAc/hexane from (10:90) up to (40:60)) to afford 29a (206 mg, 0.13 mmol, 76%) as a 
yellowish oil. TLC (Rf = 0.46 hexane/EtOAc (3:2) v/v; CAM); 
1
H NMR (400 MHz, CDCl3) δ: 7.7 (br d, 
J = 7.5 Hz, 3 H), 7.5-7.3 (m, 45 H), 6.9 (br s, 3 H), 6.7 (d, J = 9.2 Hz, 3 H), 5.09 (s, 6 H), 5.08 (s, 12 H), 
4.2 (t, J = 6.5 Hz, 6 H), 3.5 (t, J = 6.0 Hz, 6 H), 3.3 (s, 6 H), 1.9 (qn, J = 6.3 Hz, 6 H), 1.0 (s, 3 H); 
13
C 
NMR (100 MHz, CDCl3) δ: 153.5, 148.3, 141.7, 141.6, 137.3, 136.9, 136.8, 128.6, 128.5, 128.4, 128.3, 
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128.0, 127.9, 127.5, 126.3, 113.5, 109.7, 75.8, 75.5, 73.5, 71.3, 67.6, 62.4, 40.8, 29.2, 17.5; HRMS (ESI
+
) 
[M + Na]
+
 C98H99N3O18Na requires 1629.6821, found: 1629.6849.  
 
2,2-bis [5-((2,3,4-tribenzyloxyphenyl)carbamoyl)oxy-2-oxapentyl]propane (30a) 
 
A solution of acid 3 (300 mg, 0.7 mmol), DPPA (0.2 mL, 0.8 mmol) and Et3N (0.1 mL, 0.8 mmol) in 
toluene (3.4 mL) was treated as described in the general procedure and intermediate isocyanate 4 
generated in situ was treated with diol 26 (50 mg, 0.23 mmol) (stirred overnight at 95 ºC after addition of 
diol). After chromatographic purification (hexane/EtOAc (100:0) up to (80:20) v/v), isolated 30a was still 
accompanied by an impurity with a closed chromatographic mobility. In order to get a pure sample of the 
desired compound for subsequent transformations, a fraction of the pre-purified material was carefully 
purified by CCTLC (EtOAc/dichloromethane (0:100) up to (2:98) v/v) to provide an analytical pure 
sample of the desired compound 30a (43 mg, 0.04 mmol), that was obtained completely pure as a white 
foam after freeze-drying. TLC (Rf = 0.43 hexane/EtOAc (3:2) v/v; CAM); 
1
H NMR (300 MHz, CDCl3) 
δ: 7.67 (br d, J = 8.9 Hz, 2 H), 7.46-7.31 (m, 30 H), 6.89 (br s, 2 H), 6.74 (d, J = 9.2 Hz, 2 H), 5.09 (s, 4 
H), 5.08 (s, 8 H), 4.19 (t, J = 6.5 Hz, 4 H), 3.48 (t, J = 6.1 Hz, 4 H), 3.19 (s, 4 H), 1.89 (qn, J = 6.3 Hz, 4 
H), 0.91 (s, 6 H); HRMS (ESI
+
) [M + H]
+
 C67H71N2O12 requires 1095.5007, found: 1095.5008.  
 
Octyl (2,3,4-tris(benzyloxy)phenyl)carbamate (31a) 
 
A solution of acid 3 (155 mg, 0.35 mmol), DPPA (83 µL, 0.4 mmol) and Et3N (54 µL, 0.4 mmol) in 
toluene (1.8 mL) was treated as described in the general procedure and intermediate isocyanate 4 was 
reacted with octanol (66 mL, 0.42 mmol). The crude mixture was purified by CCTLC (polar gradient 
EtOAc/hexane from (5:95) up to (20:80)) and recrystallized from MeOH to yield 31a (178 mg, 0.3 mmol, 
89%) as a white solid. mp. 59.3-60.1 ºC; TLC (Rf = 0.34 hexane/EtOAc (4:1) v/v; CAM); 
1
H NMR (400 
MHz, CDCl3) δ: 7.68 (br d, 1 H), 7.4-7.3 (m, 15 H), 6.88 (br s, 1 H), 6.75 (d, J = 9.0 Hz, 1 H), 5.10 (s, 2 
H), 5.09 (s, 2 H), 5.08 (s, 2 H), 4.1 (t, J = 6.8 Hz, 2 H), 1.64 (app qn, J = 7.0 Hz, 2 H), 1.35-1.30 (m, 10 
H), 0.9 (t, J = 7.0 Hz, 3 H); 
13
C NMR (100 MHz, CDCl3) δ: 153.7, 148.2, 141.7, 137.4, 137.0, 136.9, 
128.6, 128.5, 128.4, 128.3, 128.1, 127.9, 127.5, 126.4, 113.4, 109.9, 75.9, 75.6, 71.4, 65.2, 31.8, 29.2, 
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28.9, 25.8, 22.7, 14.1; m/z (ESI
+
) 590 (67%, [M + Na]
+
), 568 (100%, [M + H]
+
); Anal. calcd for 
C36H41NO5 (567.7): C, 76.16; H, 7.28; N, 2.47; found: C, 76.24; H, 7.49; N, 2.67.  
 
Tetrakis [5-((2,3,4-tribenzyloxyphenyl)ureido)-2-oxapentyl]methane (32a) 
 
A solution of acid 3 (483 mg, 1.1 mmol), DPPA (0.26 mL, 1.2 mmol) and Et3N (0.17 mL, 1.2 mmol) in 
toluene (5.5 mL) was stirred at 70 ºC under microwave irradiation for 30 min and then tetra-amine 22 
(100 mg, 0.27 mmol) was added to react with the intermediate isocyanate 4 formed in situ. The reaction 
mixture was stirred at 100 ºC for further 90 min under microwave irradiation. Then, it was cooled to room 
temperature, subsequently washed with a 1 N aqueous solution of HCl and a saturated aqueous solution of 
NaHCO3, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by 
CCTLC (polar gradient MeOH/CH2Cl2 from (0:100) up to (6:94)) and the isolated product was 
recrystallized from MeOH-CH2Cl2 (5:1) v/v to afford 32a (96 mg, 0.045 mmol, 17%) as a yellowish 
solid. mp. 175.3-176.1 ºC; TLC (Rf = 0.36 dichloromethane/MeOH (95:5) v/v; CAM; vanillin); 
1
H NMR 
(300 MHz, CDCl3) δ: 7.58-7.13 (m, 64 H), 7.08 (br s, 4 H), 6.65 (d, J = 8.5 Hz, 4 H), 5.48 (br s, 4 H), 
5.00 (s, 8 H), 4.97 (s, 8 H), 4.95 (s, 8 H), 3.42 (br s, 8 H), 3.32 (s, 8 H), 3.19 (br s, 8 H), 1.68 (app t, 8 H); 
13
C NMR (75 MHz, CDCl3) δ: 156.4, 148.8, 143.6, 142.4, 137.8, 137.4, 137.3, 128.8, 128.7, 128.6, 128.4, 
128.3, 128.0, 127.7, 127.5, 116.6, 110.6, 76.0, 75.6, 71.9, 70.0, 69.3, 45.6, 38.1, 30.0; HRMS (ESI
+
) 
C129H133N8O20 requires MH 2114.9636, found: 2114.9663; Anal. calcd for C129H132N8O20 (2113.0): C, 
73.28; H, 6.29; N, 5.30; found: C, 73.15; H, 6.07; N, 5.31.  
 
1-Propyl-3-(2,3,4-tris(benzyloxy)phenyl)urea (33a)  
 
A solution of acid 3 (155 mg, 0.35 mmol), DPPA (83 µL, 0.39 mmol) and Et3N (54 µL, 0.39 mmol) in 
toluene (1.8 mL, 5 mL/mmol) was treated as described in the general procedure for the synthesis of 
carbamates. Intermediate isocyanate 4 was treated with n-propylamine (58 mg, 0.7 mmol) (stirred 
overnight at 100 ºC after addition of the amine). The crude was purified by CCTLC (polar gradient, 
EtOAc/CH2Cl2 from (0:100) up to (20:80)) and recrystallizated from MeOH to afford 33a (90 mg, 0.18 
mmol, 52%) as a white solid. mp. 155.1-156.3 ºC; 
1
H NMR (400 MHz, CDCl3) δ: 7.51 (d, J = 9.0 Hz, 1 
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H), 7.45-7.31 (m, 16 H), 6.74 (d, J = 9.1 Hz, 1 H), 6.50 (br s, 1 H), 5.09 (s, 4 H), 5.06 (s, 2 H), 3.04 (t, J = 
7.1 Hz, 2 H), 1.46 (sext, J = 7.3 Hz, 2 H), 0.88 (t, J = 7.4 Hz, 3 H); 
13
C NMR (100 MHz, CDCl3) δ: 155.9, 
149.1, 143.4, 142.0, 137.6, 137.3, 137.1, 128.8, 128.7, 128.5, 128.2, 128.1, 127.7, 126.6, 116.0, 110.1, 
76.3, 75.7, 71.6, 42.4, 23.3, 11.4; m/z (ESI
+
): 519 (49%, [M + Na]
+
), 497 (100%, [M + H]
+
). 
 
(2,3,4-tris(benzyloxy)phenyl)methanol (34) 
 
A solution of benzyl ester 2 (200 mg, 0.38 mmol) in fresly destilled BHT-free THF (10 mL) was flushed 
with argon. Then, LiAlH4 (29 mg, 0.75 mmol, 2 equiv) was added carefully at room temperature 
portionwise. The system was sealed under argon and refluxed for 4 h. The crude was cooled to room 
temperature, diluted with EtOAc (5 mL) and washed with saturated ammonium chloride aqueous solution 
(10 mL). Aqueous layer was additionally extracted with EtOAc (10 mL/mmol × 3) and the set of organic 
extracts were acidified with 5% HCl aqueous solution and washed with brine, dried over anhydrous 
Na2SO4, filtered and volatiles eliminated under reducer pressure. The crude material contained desired 
product 34 (>90% purity by HPLC), which was used in the subsequent transformation without further 
purification. If higher purity is required, a purification of this material by CCTLC (hexane/EtOAc (1:1) 
v/v as eluent) afforded pure alcohol 34 as a white solid (128 mg, 0.3 mmol, 80%). This product proved 
unstable. TLC (Rf = 0.30 hexane/EtOAc (2:1) v/v; PMA); 
1
H NMR (300 MHz, CDCl3) δ: 7.45-7.25 (m, 
15 H), 6.89 (d, J = 8.4 Hz, 1 H), 6.67 (d, J = 8.4 Hz, 1 H), 5.16 (s, 2 H), 5.12 (s, 2 H), 5.08 (s, 2 H), 4.50 
(d, J = 6.6 Hz, 2 H), 1.84 (t, J = 6.6 Hz, 1 H); 
13
C NMR (125 MHz, CDCl3) δ 153.0, 151.0, 141.8, 137.4, 
137.3, 136.8, 128.6, 128.5, 128.3, 128.0, 127.5, 123.7, 109.4, 75.7, 75.5, 71.0, 61.5; m/z (ESI
+
): 449 
(17%, [M + Na]
+
), 409 (68%, [M – H2O + H]
+
); HPLC/MS: tR = 5.91 min., polar gradient CH3CN/H2O 
from (10:90) up to (100:0) in 5 min (93% purity); tR = 2.79 min; polar gradient CH3CN/H2O from (70:30) 
up to (100:0) in 5 min; (92% purity). 
 
2,3,4-tris(benzyloxy)benzaldehyde (35)
3
 
 
Alcohol 35 (100 mg, 0.23 mmol, 1 equiv) was dissolved in THF (10 mL). Activated manganese oxide 
(85% purity, 102 mg, 1.17 mmol, 5 equiv) was added and the heterogeneous mixture efficiently stirred 
and refluxed for 8 h. Once verified by TLC the complete transformation, the crude was cooled to room 
temperature and filtered through a short celite pad, washing with CH2Cl2. The volatiles were eliminated 
under vacuo affording a solid (93% purity by HPLC) that was recrystallised from boiling methanol to 
gain additional purity, affording the desired compound 35 (69 mg, 0.16 mmol, 69%) as a white solid. 
TLC (Rf = 0.56 hexane/EtOAc (2:1) v/v; CAM; DNP); 
1
H NMR (300 MHz, CDCl3) δ: 10.12 (s, 1H), 7.6 
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(d, J = 8.8 Hz, 1 H), 7.5-7.3 (m,15 H), 6.84 (d, J = 8.8 Hz, 1 H), 5.21 (s, 2 H), 5.16 (s, 2 H), 5.08 (s, 2 H); 
13
C NMR (125 MHz, CDCl3) δ: 188.8, 158.6, 156.0, 141.2, 137.0, 136.3, 135.9, 128.7, 128.6, 128.5, 
128.4, 128.3, 128.2, 127.5, 124.1, 109.2, 76.8, 75.6, 71.0; m/z (ESI
+
): 447 (66%, [M + Na]
+
), 425 (100%, 
[M + H]
+
); HPLC/MS: tR = 3.66 min.; polar gradient CH3CN/H2O from (70:30) up to (100:0) in 5 min 
(95% purity). Spectroscopic properties of this compound were consistent with the data reported in the 
literature.
3 
 
Tetrakis [5-((2,3,4-tribenzyloxy)phenyloxycarbonyl)-2-oxapentyl] methane (37a)  
 
To a solution of tetra-acid 10 (26 mg, 0.06 mmol, 1 equiv) in dry CH2Cl2 (1.2 mL; 20 mL/mmol) at 0 ºC 
was added phenol 36
3
 (121 mg, 0.29 mmol, 4.8 equiv) and DCC (61 mg, 0.29 mmol). The system was 
stirred at room temperature overnight and the resulting white solid was filtered and washed with CH2Cl2. 
The filtrate liquors were washed with an aqueous 10% citric acid solution, aqueous 10% NaHCO3 
solution and H2O, dried over anhydrous Na2SO4, filtered and the solvent was eliminated under vacuo. The 
crude was purified by CCTLC on immobilised silica gel (EtOAc/hexane 30-80%) to afford 37a (76 mg, 
0.038 mmol, 62%) as a yellowish wax. TLC (Rf = 0.25 hexane/EtOAc (2:3) v/v; CAM); 
1
H NMR (400 
MHz, CDCl3) δ: 7.42-7.29 (m, 60 H), 6.77 (d, J = 9.1 Hz, 4 H), 6.71 (d, J = 9.0 Hz, 4 H), 5.10 (s, 8 H), 
5.09 (s, 8 H), 5.03 (s, 8 H), 3.70 (t, J = 6.4 Hz, 8 H), 3.44 (s, 8 H), 2.71 (t, J = 6.4 Hz, 8 H); 
13
C NMR 
(100 MHz, CDCl3) δ: 170.0, 151.1, 145.2, 142.7, 138.2, 137.4, 137.3, 136.7, 128.5, 128.4, 128.3, 128.2, 
128.0, 127.9, 127.5, 117.1, 108.6, 75.5, 75.4, 71.1, 69.6, 66.5, 45.3, 34.7; HRMS (ESI
+
) [M + Na]
+
 
C125H116O24Na requires 2023.7754, found: 2023.7749.  
 
2,3,4-tris(benzyloxy)phenyl acetate (38a) 
 
Phenol 36
3
 (135 mg, 0.33 mmol) was dissolved in dry pyridine (2 mL; 6 mL/mmol) at 0 ºC (ice-bath) and 
acetic anhydride (500 mg, 4.9 mmol) was added. The system was slowly allowed to reach room 
temperature and then left overnight with stirring. TLC analysis showed a single spot with equal mobility 
that the starting material (Rf = 0.65, hexane/EtOAc (1:1) v/v), but vanillin exhibited a different colour for 
starting material and crude. Solvent was evaporated under reduced pressure and crude redissolved in 
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CH3CN (5 mL) and volatiles eliminated. This process is repeated several times until brownish viscous oil 
remains. The crude material contains the desired product 38a which is used without further purification 
(130 mg, 0.3 mmol, 91%). TLC (Rf = 0.65 (1:1) hexane/EtOAc v/v; CAM); 
1
H NMR (400 MHz, CDCl3) 
δ: 7.5-7.2 (m, 15 H), 6.76 (d, J = 9 Hz, 1 H), 6.73 (d, J = 9 Hz, 1 H), 5.10 (s, 2 H), 5.09 (s, 2 H), 5.08 (s, 2 
H), 2.2 (s, 3 H); 
13
C NMR (100 MHz, CDCl3) δ: 169.7, 151.4, 145.4, 143.1, 138.6, 137.6, 137.5, 137.0, 
128.9, 128.8, 128.6, 128.5, 128.3, 128.2, 127.7, 117.3, 108.9, 75.8, 75.8, 71.6, 20.9; m/z (ESI
+
) 455 (90%, 
[M + H]
+
), 413 (65%, [M –Ac + H]+); HPLC: tR = 3.9 min. polar gradient CH3CN/H2O from (70:30) up to 
(95:5) in 5 min (99% purity); HPLC/MS: tR = 4.2 min., polar gradient CH3CN/H2O from (70:30) up to 
(95:5) in 5 min (96% purity). 
 
(2,3,4-tris(benzyloxy)phenyl) acetylene (39)  
 
Benzylic alcohol 34 (300 mg, 0.7 mmol) was dissolved in dry THF (15 mL; 20 mL/mmol) at room 
temperature. Activated MnO2 (Aldrich 21,764-6, 5 equiv) was added and the resulting heterogeneous 
mixture refluxed for 5 h. Once the oxidation to aldehyde was verified (TLC monitoring), the crude was 
cooled to room temperature and anhydrous MeOH (3 mL) was slowly added
16
 followed by K2CO3 (66 
mg, 0.5 mmol, 0.7 equiv). On cooling at 0 ºC, Bestmann-Ohira reagent
17
 (204 mg, 1.1 mmol, 1.6 equiv) 
was added to the heterogeneous mixture and the reaction was stirred further for 1 h at 0 ºC. Then, the 
reaction was warmed to room temperature and left stirred overnight. TLC analysis showed fully 
conversion of starting material into a less polar product. Crude was filtered through a short celite pad 
(CH2Cl2 eluent). Volatiles were eliminated under reduced pressure, the residue redissolved in CH2Cl2 (25 
mL) and washed with H2O (25 mL). Aqueous layer was additionally extracted with CH2Cl2 (3 x 20 mL), 
the whole organic layers treated with anhydrous MgSO4, filtered and solvent eliminated under vacuo. 
Crude material was purified by CCTLC on inmobilised silica gel eluting with hexane/EtOAc (9:1 v/v), 
providing acetylene 39 as a viscous oil (264 mg, 0.6 mmol, 89%). TLC (Rf = 0.55 (2:1) hexane/EtOAc 
v/v; CAM); 
1
H NMR (300 MHz, CDCl3) δ: 7.6-7.2 (m, 15 H), 7.18 (d, J = 8.6 Hz, 1 H), 6.7 (d, J = 8.6 
Hz, 1 H), 5.16 (s, 2 H), 5.11 (s, 2 H), 5.04 (s, 2 H), 3.2 (s, 1 H); 
13
C NMR (100 MHz, CDCl3) δ: 154.8, 
154.1, 142.0, 137.32, 137.23, 136.4, 128.76, 128.66, 128.60, 128.56, 128.29, 128.27, 128.07, 128.02, 
127.4, 110.2, 109.4, 80.0, 75.8, 75.6, 70.9; m/z (ESI
+
) 443 (20%, [M + Na]
+
), 421 (50%, [M + H]
+
), 261 
(100%); HPLC/MS: tR = 9.67 min., polar gradient CH3CN/H2O from (40:80) up to (95:5) in 10 min (97% 
purity). 
 
(2,3,4-tris(benzyloxy)phenyl) azide (41) 
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To a suspension of hydrochloride 8 (250 mg, 0.56 mmol) in H2O (0.4 mL; 0.7 mL/mmol) was added 
concentrated H2SO4 (0.1 mL, 2 mmol) followed by dropwise addition of a solution of NaNO2 (42 mg, 
0.61 mmol) in H2O (0.3 mL; 0.4 mL/mmol) at 0 ºC. Next, it was sequentially added hexane (1.0 mL, 1.5 
mL/mmol) and a solution of NaN3 (40 mg, 0.6 mmol) in H2O (0.3 mL; 0.5 mL/mmol). The reaction 
mixture was stirred at room temperature for further 4 hours and finally diluted with H2O. The crude 
material was extracted with EtOAc (4 × 10 mL/mmol) and the organics layers were dried over Na2SO4, 
filtered and concentrated. The crude was purified by automated flash chromatography on silica gel (polar 
gradient on elution, from hexane/EtOAc 95:5 up to hexane/EtOAc 60:40 as eluent) to isolate 41 (55 mg, 
0.13 mmol, 23%) as a yellowish solid. mp. 71.5-73.4 ºC; TLC (Rf = 0.37 hexane/EtOAc (7:3) v/v; PMA); 
1
H NMR (300 MHz, CDCl3) δ: 7.47-7.29 (m, 15 H), 6.72 (d, J = 1.2 Hz, 2 H), 5.10 (s, 2 H), 5.09 (s, 2 H), 
5.07 (s, 2 H);
 13
C NMR (75 MHz, CDCl3) δ: 150.7, 146.0, 143.7, 137.6, 137.1, 128.8, 128.7, 128.5, 128.4, 
128.3, 128.2, 127.7, 115.0, 110.8, 76.4, 75.8, 72.0; m/z (ESI
+
): 460 (100%, [M + Na]
+
). 
 
Preparation of 1,2,3-triazole-bridged compounds 40a and 43a by Copper-catalysed 1,3-dipolar 
cycloaddition azide-alkyne (Huisgen reaction). General Procedure. 
To a suspension of the corresponding azide (1 equiv per alkyne) and alkyne (1 equiv per azide) in 
tBuOH/H2O (2:1) v/v (64 mL/mmol) at room temperature was added (+)-sodium L-ascorbate (0.4 equiv) 
and CuSO4 (0.04 equiv). The heterogeneous mixture was stirred at room temperature overnight and then 
treated with H2O. The resulting solid was filtrated, washed with H2O and purified as determined.  
 
Tetrakis [5-(4-(2,3,4-tribenzyloxyphenyl)-1H-1,2,3-triazol-1-yl)-2-oxapentyl] methane (40a)  
 
 
A suspension of tetra-azide 27 (20 mg, 0.04 mmol), alkyne 39 (72 mg, 0.17 mmol), (+)-sodium L-
ascorbate (3 mg, 0.017 mmol) and CuSO4 (1 mg, 0.002 mmol) in tBuOH/H2O (2.8 mL) was treated as 
described in the general procedure. The crude solid was purified by CCTLC on silica gel (polar gradient 
on elution, EtOAc/hexane from (40:60) up to (100:0) v/v) affording 40a (75 mg, 0.04 mmol, 81%) as a 
yellowish oil. TLC (Rf = 0.32 hexane/EtOAc (3:7) v/v; PMA); 
1
H NMR (500 MHz, CDCl3) δ: 7.89 (d, J 
= 8.8 Hz, 4 H), 7.74 (s, 4 H), 7.44-7.28 (m, 60 H), 6.84 (d, J = 8.9 Hz, 4 H), 5.10 (s, 8 H), 5.08 (s, 8 H,), 
5.03 (s, 8 H), 4.31 (t, J = 7.0 Hz, 8 H), 3.35 (t, J = 5.7 Hz, 8 H), 3.33 (s, 8 H), 1.97 (qn, J = 6.4 Hz, 8 H);
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13
C NMR (125 MHz, CDCl3) δ: 152.8, 149.9, 143.1, 141.8, 137.5, 137.4, 136.7, 128.6, 128.5, 128.3, 
128.1, 128.0, 127.5, 122.5, 122.0, 118.4, 109.9, 75.6, 75.5, 70.9, 69.5, 67.6, 47.2, 45.4, 30.3; HRMS 
(ESI
+
) [M + H]
+
 C133H129N12O16 MH requires 2149.9650, found: 21.9644. 
 
Tetrakis [3-(1-(2,3,4-tribenzyloxyphenyl)-1H-1,2,3-triazol-4-yl)-2-oxapropyl] methane (43a) 
 
 
A suspension of tetra-alkyne 42
6
 (14 mg, 0.048 mmol), azide 41 (83 mg, 0.190 mmol), (+)-sodium L-
ascorbate (4 mg, 0.019 mmol) and CuSO4 (1 mg, 0.002 mmol) in tBuOH/H2O (3.0 mL) was treated as 
described in the general procedure. Additional (+)-sodium L-ascorbate (0.4 equiv) and CuSO4 (0.04 
equiv) were added to ensure fully conversion of the reaction. The crude solid was purified by CCTLC 
(EtOAc/hexane 20-100%) to afford 43a (57 mg, 0.028 mmol, 60%) as a yellowish solid. mp. 50.2-51.1 
ºC; TLC (Rf = 0.30 hexane/EtOAc (3:7) v/v; PMA); 
1
H NMR (400 MHz, CDCl3) δ: 7.78 (d, J = 2.7 Hz, 4 
H), 7.43-7.30 (m, 32 H,) 7.30-7.25 (m, 10 H), 7.21 (dd, J = 9.0, 4.6 Hz, 4 H), 7.18-7.14 (m, 10 H), 7.05-
6.98 (m, 8 H), 6.76 (d, J = 9.1 Hz, 4 H), 5.08 (s, 8 H), 5.06 (s, 8 H), 4.87 (s, 8 H,), 4.54 (s, 8 H), 3.52 (s, 8 
H); 
13
C NMR (125 MHz, CDCl3) δ: 153.8, 146.1, 145.0, 142.7, 137.2, 136.4, 136.3, 128.8, 128.7, 128.5, 
128.4, 128.3, 127.7, 125.6, 124.8, 120.5, 109.4, 76.4, 75.9, 71.3, 69.5, 65.2, 45.7; HRMS (ESI
+
) [M + H]
+
 
C125H113N12O16 requires 2037.8398, found: 2037.8392; Anal. calcd for C125H112N12O16 (2038.30): C, 
73.66; H, 5.54; N, 8.25; found: C, 73.58; H, 5.51; N, 8.19. 
 
Preparation of free polyphenols 6b, 13b-15b, 17b-21b, 23b, 28b-33b, 37-38b/38c, 40b and 43b. 
Deprotection of benzylated phenols by catalytic hydrogenation. General procedure. 
A solution of the corresponding benzyl-protected precursors (1 mmol) in a binary mixture of solvents 
THF/methanol (1:1) v/v (100 mL) containing catalytic amounts of Pd (on charcoal; 10 wt.-%) was 
hydrogenated overnight in a Parr Hydrogenator at 3.1 bar in a thermostated vessel at 25 °C.
18
 The Pd 
catalyst was removed by filtration through a Whatman® filter paper 42 and the solvent was removed 
under reduced pressure to give the corresponding deprotected free-phenolic derivatives as single products 
which were treated as specified. All debenzylated compounds should be kept at -20 ºC and protected from 
the direct exposition to light 
 
Tetrakis [5-oxo-5-((2,3,4-trihydroxyphenyl)amino)-2-oxapentyl]methane (13b) 
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A solution of 13a (50 mg, 0.025 mmol) in THF/MeOH (2.5 mL) was treated as described in the general 
procedure to afford 13b (24 mg, 0.026 mmol, quantitative yield) as a yellowish foam after freeze-drying 
without further purification. 
1
H NMR (400 MHz, CD3OD) δ: 6.70 (d, J = 8.6 Hz, 4 H), 6.32 (d, J = 9.0 
Hz, 4 H), 3.59 (t, J = 5.7 Hz, 8 H), 3.42 (s, 8 H), 2.50 (t, J = 5.7 Hz, 8 H);
 13
C NMR (100 MHz, CD3OD) 
δ: 173.7, 145.2, 140.0, 136.0, 120.4, 114.6, 108.1, 71.0, 68.7, 46.9, 38.2; m/z (ESI+) 917 (100%, [M + 
H]
+
), 477 (94%, [M/2 + NH4)]
+
); HRMS (ESI+) [M + Na]
+
 C41H48N4NaO20 requires 939.2760, found: 
939.2749; Anal. calcd for C41H48N4O20 (916.8): C, 53.71; H, 5.28; N, 6.11; found: C, 53.42; H, 5.58; N, 
6.31; HPLC: tR = 2.86 min. polar gradient CH3CN/H2O from (10:90) up to (100:0) in 5 min (96% purity). 
 
1,1,1-tris [5-oxo-5-((2,3,4-trihydroxyphenyl)amino)-2-oxapentyl]ethane (14b) 
 
A solution of 14a (63 mg, 0.042 mmol) in THF/MeOH (2.1 mL) was treated as described in the general 
procedure to afford 14b (20 mg, 0.028 mmol, 67%) as a white foam after freeze-drying without further 
purification. 
1
H NMR (500 MHz, CD3OD) δ: 6.69 (d, J = 8.8 Hz, 3 H), 6.32 (d, J = 8.8 Hz, 3 H), 3.64 (t, 
J = 5.9 Hz, 6 H), 3.32 (s, 6 H), 2.54 (t, J = 5.9 Hz, 6 H), 0.91 (s, 3 H); 
13
C NMR (125 MHz, CD3OD) δ: 
173.3, 144.9, 139.7, 135.7, 120.1, 114.2, 107.8, 74.6, 68.5, 42.0, 37.9, 18.0; m/z (ESI
+
) 706 (100%, [M + 
H]
+
); Anal. calcd for C32H39N3O15 (705.7): C, 54.47; H, 5.57; N, 5.95; found: C, 54.83; H, 5.80; N, 5.62; 
HPLC: tR = 4.67 min. polar gradient CH3CN/H2O from (10:90) up to (100:0) in 10 min (97% purity). 
 
2,2-Bis [5-oxo-5-((2,3,4-trihydroxyphenyl)amino)-2-oxapentyl]propane (15b) 
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A solution of 15a (84 mg, 0.08 mmol) in THF/MeOH (4.1 mL) was treated as described in the general 
procedure to afford 15b (22 mg, 0.044 mmol, 55%) as a yellowish foam after trituration with Et2O and 
freeze-drying. 
1
H NMR (400 MHz, CD3OD) δ: 6.68 (d, J = 8.8 Hz, 2 H), 6.32 (d, J = 8.6 Hz, 2 H), 3.69 
(t, J = 5.7 Hz, 4 H), 3.24 (s, 4 H), 2.58 (t, J = 5.7 Hz, 4 H), 0.89 (s, 6 H); 
13
C NMR (100 MHz, CD3OD) δ: 
173.3, 144.9, 139.7, 135.7, 120.1, 114.2, 107.7, 77.9, 68.4, 37.9, 37.2, 22.6; m/z (ESI
+
) 495 (100%, [M + 
H]
+
); Anal. calcd for C23H30N2O10 (494,5): C, 55.87; H, 6.12; N, 5.67; O, 32.36; found: C, 55.57; H, 6.05; 
N, 5.44; HPLC: tR = 5.28 min., polar gradient CH3CN/H2O from (10:90) to (100:0) in 10 min (100% 
purity). 
 
Tetrakis [5-oxo-5-((3,4,5-trihydroxyphenyl)amino)-2-oxapentyl]methane (17b) 
 
A solution of 17a (58 mg, 0.03 mmol) in THF/MeOH (1.5 mL) was treated as described in the general 
procedure to afford 17b (17 mg, 0.02 mmol, 64%) as a white foam after trituration with Et2O and freeze-
drying. 
1
H NMR (500 MHz, CD3OD) δ: 6.65 (s, 8 H), 3.56 (t, J = 5.7 Hz, 8 H), 3.33 (s, 8 H), 2.41 (t, J = 
5.5 Hz, 8 H); 
13
C NMR (125 MHz, CD3OD) δ: 171.0, 145.5, 130.1, 129.8, 100.2, 69.2, 67.1, 45.2, 37.2; 
m/z (ESI
+
) 917 (100%, [M + H]
+
); HPLC: tR = 2.62 min. polar gradient CH3CN/H2O from (10:90) up to 
(95:5) in 5 min (95% purity). 
 
Tetrakis [5-(methyl((3,4,5-trihydroxyphenyl)amino))-5-oxo-2-oxapentyl] methane (18b) 
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A solution of 18a (46 mg, 0.022 mmol) in THF/MeOH (1.1 mL) was treated as described in the general 
procedure to obtain 18b (12 mg, 0.012 mmol, 56%) as a yellowish waxy solid after trituration with Et2O 
and freeze-drying. 
1
H NMR (300 MHz, CD3OD) δ: (some signals appear broadened) 6.49-6.42 (m, 4 H), 
6.35 (d, J = 8.6 Hz, 4 H), 3.61-3.49 (m, 4 H), 3.49-3.37 (m, 4 H), 3.16 (s, 8 H), 3.12 (s, 12 H), 2.38 (dt, J 
= 14.5, 7.2 Hz, 4 H), 2.29-2.11 (m, 4 H); m/z (ESI
+
) 974 (18%, [M + H]
+
), 487 (100%, [(M + 2H)/2]
+
); 
HPLC: tR = 2.73 min. polar gradient CH3CN/H2O from (15:85) up to (95:5) in 5 min (96% purity). 
 
N-(2,3,4-trihydroxyphenyl)acetamide (19b) 
 
A solution of 19a (65 mg, 0.14 mmol) in THF/MeOH (7 mL) was treated as described in the general 
procedure. The crude product was freeze-dried to obtain 19b (25 mg, 0.14 mmol, 95%) as a yellowish 
solid after purification by a solid phase extraction using a Varian Mega BE-SCX resin (1 g, 6 mL; 
activation of the resin using MeOH, load and wash using CH2Cl2/MeOH and liberation with a 2 N 
ammonium solution in MeOH). mp. 88.7-89.9 ºC; TLC (Rf = 0.18 hexane/EtOAc (3:7) v/v; PMA); 
1
H 
NMR (400 MHz, CD3OD) δ: 6.59 (d, J = 8.7 Hz, 1 H), 6.32 (d, J = 8.8 Hz, 1 H), 2.15 (s, 3 H); 
13
C NMR 
(100 MHz, CD3OD) δ: 173.0, 145.5, 140.5, 136.3, 120.4, 115.1, 108.2, 23.3; m/z (ESI
+
) 184 (100%, [M + 
H]
+
); HPLC: tR = 2.27 min. polar gradient CH3CN/H2O from (2:98) to (30:70) in 5 min (98% purity). 
 
N-(2,3,4-trihydroxyphenyl)propionamide (20b) 
 
A solution of 20a (70 mg, 0.15 mmol) in THF/MeOH (9 mL) was treated as described in the general 
procedure to yield 20b (23 mg, 0.12 mmol, 78%) as a white solid after recrystallization from EtOAc-
hexane. mp. 128.3-129.3 ºC; 
1
H NMR (400 MHz, CD3OD) δ: 6.59 (d, J = 8.8 Hz, 1 H), 6.32 (d, J = 8.8 
Hz, 1 H), 2.42 (qt, J = 7.6 Hz, 2 H), 1.20 (t, J = 7.6 Hz, 3 H); 
13
C NMR (100 MHz, CD3OD) δ: 176.5, 
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145.4, 140.4, 136.3, 120.6, 114.8, 108.3, 30.8, 11.0; m/z (ESI
+
) 215 (26%, [M + Na]
 +
), 198 (100%, [M + 
H]
+
); Anal. calcd for C9H11NO4 (197.2): C, 52.46; H, 4.95; N, 7.65; found: C, 52.27; H, 5.19; N, 7.90; 
HPLC: tR = 1.54 min. polar gradient CH3CN/H2O from (10:90) up to (100:0) in 5 min (95% purity). 
 
N-(2,3,4-trihydroxyphenyl)palmitamide (21b) 
 
A solution of 21a (37 mg, 0.06 mmol) in THF/MeOH (3 mL) was treated as described in the general 
procedure to yield 21b (12 mg, 0.032 mmol, 55%) as a brownish solid after recrystallization from hexane. 
mp. 94.7-95.8 ºC; 
1
H NMR (400 MHz, CD3OD) δ: 6.55 (d, J = 8.7 Hz, 1 H), 6.30 (d, J = 8.7 Hz, 1 H), 
2.38 (t, J = 7.5 Hz, 2 H), 1.67 (qn, J = 7.3 Hz, 2 H), 1.45-1.17 (m, 24 H), 0.88 (t, J = 6.9 Hz, 3 H); 
13
C 
NMR (100 MHz, CD3OD) δ: 175.4, 144.9, 139.9, 135.9, 120.1, 114.3, 107.8, 37.1, 33.1, 30.8, 30.7, 30.6, 
30.5, 30.3, 27.1, 23.7, 14.4; m/z (ESI
+
) 380 (100%, [M + H]
+
); Anal. calcd for C22H37NO4 (379.5): C, 
69.62; H, 9.83; N, 3.69; found: C, 69.46; H, 10.04; N, 3.82;
 
HPLC: tR = 2.13 min. polar gradient 
CH3CN/H2O from (90:10) up to (100:0) in 5 min (98% purity). 
 
Tetrakis [5-(3-(2,3,4-trihydroxy)benzamido)-2-oxapentyl]methane (23b) 
 
A solution of 23a (92 mg, 0.05 mmol) in a mixture of THF/MeOH (2 mL) was treated as described in the 
general hydrogenation procedure to provide 23b (30 mg, 0.03 mmol, 69%) as a yellowish waxy solid that 
was converted after freeze-drying in a foam that was used without further purification. 
1
H NMR (500 
MHz, CD3OD) δ: 7.10 (d, J = 8.8 Hz, 4 H), 6.34 (d, J = 8.8 Hz, 4 H), 3.41 (t, J = 5.9 Hz, 8 H), 3.40 (t, J = 
6.9 Hz, 8 H), 3.36 (s, 8 H), 2.17 (qn, J = 6.4 Hz, 8 H); 
13
C NMR (125 MHz, CD3OD) δ 171.7, 151.5, 
150.6, 134.0, 119.1, 109.0, 107.8, 71.1, 70.5, 46.6, 38.2, 30.5; m/z (ESI
+
): 974 (40%, [M + H]
+
), 487 
(100%, [(M + 2H)/2]
+
); HRMS (ESI+) [M + H]
+
 C45H57N4O20 requires 973.3566, found: 973.3571; 
HPLC: tR = 6.07 min. polar gradient CH3CN/H2O from (10:90) up to (100:0) in 10 min (95% purity). 
 
Tetrakis [5-((2,3,4-trihydroxyphenyl)carbamoyl)oxy-2-oxapentyl]methane (28b) 
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A solution of 28a (70 mg, 0.033 mmol) in THF/MeOH (2 mL) was treated as described in the general 
procedure to yield 28b (22 mg, 0.04 mmol, 64%) as a brownish foam after freeze-drying and used 
without further purification. 
1
H NMR (400 MHz, CD3OD) δ: 6.73 (br d, J = 8.2 Hz, 4 H), 6.30 (d, J = 9.0 
Hz, 4 H), 4.18 (t, J = 6.4 Hz, 8 H), 3.49 (app t, 8 H), 3.39 (s, 8 H), 1.88 (br t, J = 5.9 Hz, 8 H);
 13
C NMR 
(100 MHz, CD3OD) δ: 157.4, 144.2, 139.5, 135.2, 119.8, 114.2, 107.4, 70.6, 68.7, 63.7, 46.7, 30.3; m/z 
(ESI
+
) 1038 (100%, [M + H]
+
); HRMS (ESI+) [M + H]
+
 C45H57N4O24 requires 1037.3363, found: 
1037.3374; Anal. calcd for C45H56N4O24 (1036.9): C, 52.12; H, 5.44; N, 5.40; found: C, 51.96; H, 5.38; 
N, 5.24; HPLC: tR = 5.83 min. polar gradient CH3CN/H2O from (10:100) up to (100:0) in 10 min (96% 
purity). 
 
1,1,1-tris [5-((2,3,4-trihydroxyphenyl)carbamoyl)oxy-2-oxapentyl]ethane (29b) 
 
A solution of 29a (55 mg, 0.03 mmol) in THF/MeOH (2 mL) was treated as described in the general 
procedure to yield 29b (20 mg, 0.02 mmol, 74%) as a yellowish foam after freeze-drying and used 
without further purification. 
1
H NMR (500 MHz, CD3OD) δ: 6.63 (br d, J = 6.9 Hz, 3 H), 6.20 (d, J = 8.7 
Hz, 3 H), 4.09 (t, J = 6.4 Hz, 6 H), 3.40 (app t, 6 H), 3.20 (s, 6 H), 1.80 (br t, J = 5.9 Hz, 6 H), 0.83 (s, 3 
H);
 13
C NMR (125 MHz, CD3OD) δ: 150.8, 143.9, 142.8, 133.7, 120.2, 112.7, 106.0, 73.1, 67.3, 62.2, 
40.6, 28.9, 16.6; m/z (ESI
+
) 796 (100%, [M + H]
+
); Anal. calcd for C35H45N3O18 (795,7): C, 52.83; H, 
5.70; N, 5.28; O, 36.19; found: C, 52.64; H, 6.03; N, 5.02; HPLC: tR = 6.10 min. polar gradient 
CH3CN/H2O from (10:100) up to (100:0) in 10 min (95% purity). 
 
2,2-Bis [5-((2,3,4-trihydroxyphenyl)carbamoyl)oxy-2-oxapentyl] propane (30b) 
 
A.Flores et al. S28 Electronic Supplementary Information 
 
A solution of 30a (43 mg, 0.04 mmol) in THF/MeOH (2 mL) was treated as described in the general 
procedure to yield 30b (21 mg, 0.038 mmol, 97%) as a yellowish foam after freeze-drying and used 
without further purification. 
1
H NMR (400 MHz, CD3OD) δ: 6.73 (br d, J = 7.0 Hz, 2 H), 6.30 (d, J = 8.8 
Hz, 2 H), 4.20 (t, J = 6.4 Hz, 4 H), 3.51 (app t, 4 H), 3.31 (s, 4 H), 1.91 (br t, J = 5.9 Hz, 4 H), 0.88 (s, 6 
H); 
13
C NMR (100 MHz, CD3OD) δ: 157.5, 144.3, 139.6, 135.2, 119.8, 114.1, 107.3, 77.9, 68.7, 63.7, 
37.2, 30.4, 22.6; m/z (ESI
+
) 555 (100%, [M + H]
+
); Anal. calcd for C25H34N2O12 (554,5): C, 54.15; H, 
6.18; N, 5.05; O, 34.62; found: C, 53.86; H, 6.27; N, 4.90; HPLC: tR = 6.66 min. polar gradient 
CH3CN/H2O from (10:90) up to (100:0) in 10 min (96% purity). 
 
Methyl (2,3,4-trihydroxyphenyl)carbamate (6b) 
 
A solution of 6a (73 mg, 0.16 mmol) in THF/MeOH (8 mL) was treated as described in the general 
procedure. The crude was purified by CCTLC (polar gradient on elution hexane/EtOAc (80:20) up to 
(0:100) v/v) to yield 6b (10 mg, 0.050 mmol, 32%) as a white foam after freeze-drying. TLC (Rf = 0.16 
hexane/EtOAc (2:3) v/v; PMA); 
1
H NMR (400 MHz, CD3OD) δ: 6.73 (d, J = 8.1 Hz, 1 H), 6.29 (d, J = 
8.8 Hz, 1 H), 3.75 (s, 3 H); m/z (ESI
+
) 200 (100%, [M + H]
+
); HPLC: tR = 2.13 min. polar gradient 
CH3CN/H2O from (90:10) up to (100:0) in 5 min (97% purity). 
 
Octyl (2,3,4-trihydroxyphenyl)carbamate (31b) 
 
A solution of 31a (90 mg, 0.16 mmol) in THF/MeOH (8 mL) was treated as described in the general 
procedure. The crude product was purified by CCTLC on silica gel (EtOAc/hexane 10-50%) and 
recrystallized, first in CH2Cl2 and secondly in CH2Cl2/hexane, to yield 31b (36 mg, 0.121 mmol, 76%) as 
a white solid. mp. 96.1-98.9 ºC; TLC (Rf = 0.39 hexane/EtOAc (2:3) v/v; PMA); 
1
H NMR (400 MHz, 
CD3OD) δ: 6.72 (br d, J = 7.8 Hz, 1 H), 6.30 (d, J = 8.6 Hz, 1 H), 4.11 (t, J = 6.5 Hz, 2 H), 1.67 (app qn, J 
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= 7.0 Hz, 2 H), 1.41-1.31 (m, 10 H), 0.91 (t, J = 7.0 Hz, 3 H); 
13
C NMR (100 MHz, CD3OD) δ: 157.6, 
144.2, 135.2, 119.8, 114.2, 107.3, 66.4, 33.0, 30.4, 30.2, 27.0, 23.7, 14.4; m/z (ESI
+
) 298 (100%, [M + 
H]
+
); Anal. calcd for C15H23NO5 (297,3): C, 60.59; H, 7.80; N, 4.71; C, 60.81; H, 7.94; N, 4.71; HPLC: tR 
= 4.97 min. polar gradient CH3CN/H2O from (10:90) up to (100:0) in 5 min (98% purity). 
 
Tetrakis [5-((2,3,4-trihydroxyphenyl)ureido)-2-oxapentyl]methane (32b) 
 
A solution of 32a (51 mg, 0.024 mmol) in THF/MeOH (1.5 mL) was treated as described in the general 
procedure to afford 32b (11 mg, 0.01 mmol, 44%) as a yellowish foam after trituration with Et2O and 
freeze-drying. This compouind was used without further purification. 
1
H NMR (400 MHz, CD3OD) δ: 
6.55 (d, J = 8.7 Hz, 4 H), 6.29 (d, J = 8.7 Hz, 4 H), 3.45 (t, J = 5.8 Hz, 8 H), 3.34 (s, 8 H), 3.26 (t, J = 6.6 
Hz, 8 H), 1.74 (app t, 8 H); m/z (ESI
+
) 517.51 (100%, [(M + 2H)/2]
+
); HPLC: tR = 4.94 min. polar 
gradient CH3CN/H2O from (10:90) up to (100:0) in 10 min (82% purity). 
 
1-Propyl-3-(2,3,4-trihydroxyphenyl)urea (33b) 
 
A solution of 33a (52 mg, 0.10 mmol) in THF/MeOH (5 mL) was treated as described in the general 
procedure to afford 33b (24 mg, 0.106 mmol, quantitative) as a brown foam after freeze-drying and used 
without further purification. 
1
H NMR (400 MHz, CD3OD) δ: 6.55 (d, J = 8.7 Hz, 1 H), 6.26 (d, J = 8.7 
Hz, 1 H), 3.11 (t, J = 7.0 Hz, 2 H), 1.51 (sext, J = 7.3 Hz, 2 H), 0.90 (t, J = 7.4 Hz, 3 H); 
13
C NMR (100 
MHz, CD3OD) δ: 159.8, 143.8, 135.6, 121.0, 113.8, 107.6, 42.9, 24.4, 11.6; m/z (ESI
+
) 227 (100%, [M + 
H]
+
); Anal. calcd for C10H14N2O4 (226,2): C, 53.09; H, 6.24; N, 12.38; O, 28.29; found: C, 53.33; H, 6.40; 
N, 12.19; HPLC: tR = 4.00 min. polar gradient CH3CN/H2O from (10:90) up to (100:0) in 10 min (95% 
purity). 
 
Tetrakis [5-((2,3,4-trihydroxy)phenyloxycarbonyl)-2-oxapentyl]methane (37b) 
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A solution of 37a (56 mg, 0.03 mmol) in THF/MeOH (1.5 mL) was treated as described in the general 
procedure to afford 37b (25 mg, 0.027 mmol, 97%) as a yellowish wax after freeze-drying and used 
without further purification. This compound proved unstable when in solution or stored for longer time. 
1
H NMR (400 MHz, CD3OD) δ: 6.35 (d, J = 8.8, 4 H), 6.30 (d, J = 8.8 Hz, 4 H), 3.77 (t, J = 6.1 Hz, 8 H), 
3.51 (s, 8 H), 2.79 (t, J = 6.0 Hz, 8 H).  
 
2,3,4-Trihydroxyphenyl acetate / 1,3,4- trihydroxyphenyl acetate (38b/38c) 
 
A solution of 38a (75 mg, 0.17 mmol) in THF/MeOH (2 mL) was treated as described in the general 
procedure to afford a mixture of compounds 38b/38c (31 mg, 1.6 mmol, quantitative yield) as a brownish 
wax after repeated freeze-drying. Hydrogenated product is found to be a mixture of 38b/38c in a 
proportion (2:1) as determined from the 
1
H-NMR data. Unstable compound. 
1
H NMR (300 MHz, 
CD3OD) δ: (taken from the (2:1) isomeric mixture of 38b/38c): 6.52 (d, J = 8.7 Hz, 1/3 H; isomer c), 6.32 
(d, J = 8.7 Hz, 2/3 H; isomer b), 6.3 (d, J = 8.7 Hz, 2/3 H; isomer b), 6.27 (d, J = 8.7 Hz, 1/3 H, isomer c), 
2.29 (s, 1 H, isomer c), 2.24 (s, 2 H, isomer b).  
 
Tetrakis [5-(4-(2,3,4-trihydroxyphenyl)-1H-1,2,3-triazol-1-yl)-2-oxapentyl] methane (40b) 
 
A solution of 40a (70 mg, 0.03 mmol) in THF/MeOH (1.5 mL) was treated as described in the general 
procedure to afford 40b (21 mg, 0.02 mmol, 60%) as a white foam after freeze-drying and used without 
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further purification. 
1
H NMR (400 MHz, CD3OD) δ: 8.14 (s, 4 H), 7.12 (d, J = 8.5 Hz, 4 H), 6.42 (d, J = 
8.6 Hz, 4 H), 4.41 (t, J = 6.6 Hz, 8 H), 3.26 (t, J = 5.6 Hz, 8 H), 3.09 (s, 8 H), 2.07 (qn, J = 6.0 Hz, 8 H);
 
13
C NMR (100 MHz, CD3OD) δ: 147.3, 147.2, 145.7, 134.3, 122.2, 118.0, 109.6, 108.5, 70.9, 69.2, 49.3, 
46.2, 31.1; HRMS (ESI
-
) C49H55N12O16 requires M-H 1067.3859, found: 1067.3864; HPLC: tR = 6.31 min. 
polar gradient CH3CN/H2O from (10:90) up to (100:0) in 10 min (95% purity). 
 
Tetrakis [3-(1-(2,3,4-trihydroxyphenyl)-1H-1,2,3-triazol-4-yl)-2-oxapropyl] methane (43b) 
 
A solution of 43a (50 mg, 0.025 mmol) in THF/MeOH (1.5 mL) was treated as described in the general 
procedure to afford 43b (20 mg, 0.02 mmol, 85%) as a white foam after trituration with cold Et2O and 
freeze-drying. 
1
H NMR (400 MHz, CD3OD) δ: 8.20 (s, 4 H), 6.85 (d, J = 8.8 Hz, 4 H), 6.43 (d, J = 8.8 
Hz, 4 H), 4.59 (s, 8 H), 3.35 (s, 8 H); 
13
C NMR (100 MHz, CD3OD) δ: 148.1 and 145.6, 141.1, 135.2, 
126.4, 119.2, 116.1, 107.7, 70.0, 65.3, 46.6; HRMS (ESI
-
) C41H39N12O16 requires M-H  955.2607, found: 
955.2619; HPLC: tR = 4.91 min. polar gradient CH3CN/H2O from (10:90) up to (100:0) in 10 min (98% 
purity).  
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